Full Answer
Why did Regeneron donate money to a non-profit?
Still no. Here’s what Regeneron did: It donated money to a nonprofit patient assistance foundation — a disappointingly necessary and common practice — so the foundation could help patients afford their copays on a medically necessary treatment that staves off blindness. Regeneron was, essentially and entirely, simply paying Medicare.
How many FDA-approved medicines does Regeneron have?
Our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved medicines for people with serious diseases. Unlike at many other biopharma companies, all these medicines were invented in our own laboratories and advanced under the consistent guidance of the Regeneron team.
What is the Patient Assistance Support Program (pass)?
The Patient Assistance Support program, PASS (the “Program”), is an assistance program supported by Regeneron Pharmaceuticals, Inc., and its aliates and agents that provides qualifying patients with Regeneron products at no cost. Authorization to Disclose Information:
What challenges have we faced at Regeneron?
we rise to any challenge with characteristic drive and a focus on scientific innovation. We’re applying our novel technologies to respond swiftly to public health infectious disease outbreaks like Ebola, MERS and COVID-19. Alumni of Regeneron’s STEM programs and competitions have won National Medals of Science, Fields Medals and Nobel Prizes.
See more
What diseases does Regeneron treat?
Our clinical portfolio currently includes antibody candidates for over 30 types of cancer, including cutaneous squamous cell carcinoma, basal cell carcinoma, non-small cell lung cancer, cervical, diffuse large B-cell lymphoma, follicular lymphoma, multiple myeloma, ovarian, prostate cancers and many more.
How do you request Regeneron?
To request infusion of monoclonal antibodies and a medical team at your facility, you may call the 24-hour State Infusion Hotline at 1- 800- 742- 5990. An Infusion Specialist will record your information and process your request.
How do I contact Regeneron?
Please call 1-844-REGN-MID (1-844-734-6643) for further information.
What type of company is Regeneron?
biotechnology companyRegeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases.
Who is eligible for Regeneron antibodies?
To qualify for Paxlovid, you must have tested positive for COVID-19, and treatment must begin within five days of the start of your symptoms. Other qualifications for Paxlovid include: You must be 12 years old or older. Weigh at least 88 pounds.
Who is eligible for Regeneron Covid treatment?
The U.S. Food and Drug Administration (FDA) has granted an Emergency Use Authorization (EUA) for REGEN-COV® (casirivimab and imdevimab) for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of ...
How long do Regeneron treatments take?
If you are receiving an intravenous infusion, the infusion will take 20 to 50 minutes or longer. o After the initial dose, if your healthcare provider determines that you need to receive additional doses of REGEN-COV for ongoing protection, the additional intravenous or subcutaneous doses would be administered monthly.
How soon does Regeneron have to be given?
A. The EUA authorizes REGEN-COV to be administered as soon as possible after a positive viral test for COVID-19 and within 10 days of symptom onset. REGEN-COV is authorized for intravenous infusion, and intravenous infusion is strongly recommended.
What is the age limit for Regeneron?
Healthcare providers should consider the benefit-risk for an individual patient. Treatment: The dosage in adult and pediatric patients (12 years of age and older weighing at least 40 kg) is 600 mg of casirivimab and 600 mg of imdevimab administered together as a single intravenous infusion or by subcutaneous injection.
Does Regeneron pay well?
Salaries at Regeneron Inc range from an average of $59,332 to $173,077 a year. Regeneron Inc employees with the job title Research Scientist make the most with an average annual salary of $101,422, while employees with the title Research Associate, Biotechnology make the least with an average annual salary of $73,273.
What makes Regeneron unique?
One of the things that's made Regeneron really unique is its willingness to invest in cutting edge technologies. We're one of the few companies in the world that go all the way from foundational discovery, to research, from research to development, to manufacturing and commercialization.
Has Regeneron been FDA approved?
REGEN-COV (casirivimab and imdevimab) is not authorized for pre-exposure prophylaxis for prevention of COVID-19. REGEN-COV has been authorized by FDA for the emergency uses described above. REGEN-COV is not FDA-approved for these uses.
How soon does Regeneron have to be given?
A. The EUA authorizes REGEN-COV to be administered as soon as possible after a positive viral test for COVID-19 and within 10 days of symptom onset. REGEN-COV is authorized for intravenous infusion, and intravenous infusion is strongly recommended.
How is Regeneron treatment given?
REGEN-COV can be administered by IV infusion (as short as 20 minutes) or by SC injection (four injections), which is an alternative when IV infusion is not feasible and would lead to a delay in treatment. It is now authorized as a co-formulated single vial, or in individual vials to be administered together.
What is the age limit for Regeneron?
Healthcare providers should consider the benefit-risk for an individual patient. Treatment: The dosage in adult and pediatric patients (12 years of age and older weighing at least 40 kg) is 600 mg of casirivimab and 600 mg of imdevimab administered together as a single intravenous infusion or by subcutaneous injection.
What are the possible side effects of taking Regeneron to treat COVID-19?
after infusion or injection, including fever, difficulty breathing, rapid or slow heart rate, tiredness, weakness or confusion. If these symptoms occur, contact your healthcare provider or seek immediate medical attention as some of these symptoms have required hospitalization.
What is Regeneron's belief?
We believe that patients should have access to appropriate, evidence-based medicines to get them to the best health. Patients are singularly able to tell their story about access challenges and how these obstacles can impact their daily lives and health. Regeneron has supported advocacy training, distribution of access tools, town halls and coalition building for patients and caregivers so that they can have a greater chance for successful outcomes. To submit a request for funding, visit our grants portal.
What is compassionate use policy?
Our Compassionate Use Policy gives certain patients who have serious or life-threatening conditions access to a potentially beneficial medicine when no comparable or satisfactory alternative therapy options or clinical trials area available. Compassionate Use, also known as expanded access in the U.S., is an approved pathway that, by design, is meant for exceptional circumstances. Our Compassionate Use program has certain established criteria and each request is reviewed by Regeneron’s Compassionate Use Committee.
What is patient advocacy?
We recognize that patient advocacy groups represent their respective patient communities’ needs, issues and challenges and can also help to raise awareness, empower patients through education and advocate for patients to receive the best care. We aim to develop meaningful, long-term relationships with patient advocacy groups and to collaborate on addressing important health issues that result in positive patient outcomes.
When was the Antibody Cocktail approved?
Data from this trial ultimately supported the U.S. Food and Drug Administration’s approval of our antibody cocktail on Oct. 14, 2020.
Is Regeneron a fast response?
To address emerging or rapidly spreading infectious diseases, Regeneron has applied our VelociSuite ® technologies in a ‘rapid response’ manner that parallel tracks certain steps and speeds hand-offs between groups in order to advance novel antibody treatments extremely quickly. We’ve been proud to apply our homegrown technologies and novel scientific approach to respond to public health challenges like Ebola, Middle East Respiratory Syndrome (MERS) and COVID-19.
Is manufacturing antibodies a process?
Manufacturing biologic medicines like antibodies is a time-consuming and precise process, and unfortunately biology can’t be hurried along. Despite the risks and uncertainties, we purposefully began this effort as early as possible so that we would have as many doses as possible immediately available for people around the world.
Scientific trailblazers
Following the science leads to unexpected breakthroughs and diverse areas of study.
Developing new medicines for serious diseases
A primarily ‘homegrown’ pipeline of potential medicines for dozens of diseases.
Over 30 years of challenges and triumphs
Our story is unusual, with remarkable consistency of leadership and purpose in our efforts to accelerate the drug discovery and development process.
Life-changing medicines
Our unique ability to repeatedly and consistently translate science into medicine has led to the discovery and development of nine FDA-approved medicines.
Our responsible business
Helping people with serious diseases involves more than just discovering new medicines. We are committed to being responsible corporate citizens who actively improve circumstances for patients, physicians, our colleagues and our broader communities.
Join our team
MD, PhD, PharmD. Over 1,100 of our colleagues hold these prestigious degrees. Whether it’s in the laboratory or conference room, every physician-scientist at Regeneron brings valuable perspective and expertise – just ask our Chief Executive Officer and Chief Scientific Officer.
Responding to COVID-19
We’re applying more than 30 years of scientific and technology expertise to combat the COVID-19 pandemic. Our novel antibody cocktail was discovered and developed in record time, and is now available to patients under Emergency Use Authorization and ongoing clinical trials.
What did Regeneron do?
Here’s what Regeneron did: It donated money to a nonprofit patient assistance foundation — a disappointingly necessary and common practice — so the foundation could help patients afford their copays on a medically necessary treatment that staves off blindness. Regeneron was, essentially and entirely, simply paying Medicare.
Why is Regeneron so inaccessible to poor patients?
To make it inaccessible to poorer patients because they can’t afford the copay is to condemn them to get more injections in their eyes and/or to progress towards blindness. Regeneron’s so-called kickbacks are just leveling the playing field between rich and poor.
What does the Massachusetts state attorney's office say about Medicare copays?
attorney’s office in Massachusetts says that Medicare copays “encourage market forces to serve as a check on health care costs.”. That sounds rational enough.
Why does Medicare not insure patients?
Any time a patient avoids a drug because she or he cannot afford Medicare’s required copayment, Medicare has failed to insure that patient. The U.S. government has failed that patient, charging taxes for empty promises. Congress knows that Medicare charges excessive out-of-pocket costs.
Why did Regeneron donate money to charity?
So Regeneron donated money to a charity so it could help patients pay Medicare’s egregiously high out-of-pocket costs.
What is encouraging copay?
So what is this copay “encouraging” or nudging patients to do? The answer is simple: It makes someone think, “Do I really need this treatment?” The copay is there so you don’t “overuse” services your insurer (in this case Medicare) has to pay for.
Why do insurance companies play off one another?
When two drugs are similar enough, insurance plans play them off one another to get rebates and require patients to at least try the less expensive drug first.
What charity did Regeneron use to help patients?
In 2019, the charity that Regeneron used to operate its patient assistance program, the Chronic Disease Fund, paid $2 million to resolve allegations that it had served as a conduit to companies paying kickbacks to Medicare patients taking their drugs. That settlement involved its work with five other companies: Novartis, Dendreon, Astellas, Onyx, and Questcor. The charity, which has been renamed Good Days, did not respond to a request for comment.
What is the Regeneron lawsuit?
District Court of Massachusetts in Boston, claims that Regeneron violated federal anti-kickback laws by using the patient-assistance fund to encourage doctors to prescribe their drug, Eylea, over a less-expensive competitor.
How much is Avastin compared to Lucentis?
Although the three drugs have been found to have comparable efficacy, Avastin is much cheaper at $55 a dose, compared with $2,000 a dose for Lucentis and $1,850 for Eylea, according to the federal lawsuit.
What is the best eye medicine?
Eylea is Regeneron’s top-selling drug, bringing in more than $4.6 billion in 2019, and treats a common eye disease in older people known as wet macular degeneration. It competes with Lucentis, as well as Avastin, a similar drug also sold by Genentech.
How much did United Therapeutics pay to settle allegations?
In 2017, United Therapeutics paid $210 million to settle similar allegations, and several other drugmakers have disclosed that they are also under investigation for their use of patient-assistance charities. In 2019, the charity that Regeneron used to operate its patient assistance program, the Chronic Disease Fund, ...
Where is Regeneron located?
Regeneron’s offices in Tarrytown, N.Y. Credit... Suzanne DeChillo/The New York Times. By Katie Thomas. June 24, 2020. The drugmaker Regeneron funneled tens of millions of dollars to a charity that paid the out-of-pocket costs for patients who took the company’s expensive eye drug, then lied to internal auditors about it, ...
Is Eylea more affordable than Avastin?
As a result, the patient assistance program was integral to driving sales of Eylea, the prosecutors said, because it made Eylea more affordable than Avastin. In 2014, for example, when a large retina clinic heard that the Chronic Disease Fund may have run out of funds, it started “putting patients only on Avastin,” according to an email from a Regeneron sales representative that was included in the lawsuit.